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The airways of patients with cystic ﬁbrosis (CF) are chronically infected with
bacteria, which theoretically poses a risk of microbial contamination of inhaler
devices. Inhaled dry powder mannitol has been investigated in patients with CF,
showing improvement in FEV1, evidence of decreasing exacerbations, and no
increase in qualitative or quantitative sputum microbial growth over a 6 month
period. Mannitol can be used in the microbiology laboratory as a substrate for
certain bacteria in vitro, and therefore we investigated the potential risk of bacterial
growth on the device after 1 week of twice daily mannitol use.
Methods: Eighty-ﬁve devices from 34 CF patients (1−3 per patient returned) were
analysed for microbial content after 1 week’s use. The presence of P. aeruginosa,
S. aureus, MRSA, Candida, yeasts, Aspergillus, coliforms, Burkholderia and
Stenotrophomonas was determined. Cultures were examined daily during the ﬁrst
week, then weekly until the end of the incubation period for each media.
Results: There was no microbiological growth on 82/85 (96.5%) inhalers. Microbi-
ological growth was reported in one device from each of 3 patients (S. aureus and
MRSA, Aspergillus, Candida). In all 3 patients, the contaminated device was the
ﬁrst of 3 used, with subsequent inhalers testing negative for growth of pathogens.
None of the 3 patients reported an acute pulmonary exacerbation during the 6 month
trial period.
Conclusions: These data suggest that contamination with CF-speciﬁc pathogens
is infrequent after 1 week of use of the inhaler, the recommended duration of
use. There was no increase in acute pulmonary exacerbation in patients with a
contaminated device.
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Results of the 2nd international double blind phase III (DBP) trial of inhaled precision
formulated Mannitol (400mg twice daily [bd]) demonstrated a sustained clinically
meaningful FEV1 improvement from baseline over 26 wks of 8.2% (106.5mL) (95%CI:
5.57, 10.88, p< 0.001) compared to 4.5% (52.4mL) (95%CI: 1.44, 7.50) on control
(D3.8%, p = 0.029 and D54.1mL, p = 0.059).[1] This open label phase (OLP) aimed to
further assess safety and efﬁcacy of Mannitol for 6−12mnths.
Methods: All 260 patients who completed the DBP continued into the OLP and
received active treatment at 400mg bd. The OLP included patient visits at wks 38
and 52, to assess safety and lung function.
Results: 242 (93.1%) patients completed the OLP, 143 (93.5%) and 99 (92.5%) initially
randomised to Mannitol and control respectively.
Patients initially randomised to Mannitol maintained the increase in FEV1 seen in
the DBP throughout the OLP with an 8.2% (87.2mL) change from baseline at wk
52. Control patients had an absolute mean FEV1 improvement from baseline of 6.3%
(84.0mL, p = 0.031) at wk 52. Overall adverse event (AE) rates reported in the OLP
were similar to the DBP of the study. The 3 most frequently reported treatment related
AEs during the OLP were condition aggravated indicating an exacerbation of CF
(4.6%); cough (1.9%) and haemoptysis (2.3%), all lower than in the DBP.
Conclusions: Mannitol shows sustained improvement in FEV1 up to 12 mnths. Patients
randomised to control in the DBP, who received active for the OLP, showed a similar
beneﬁt at the end of the study to those initially randomised to Mannitol, further
conﬁrming the efﬁcacy and safety of Mannitol therapy.
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Most patients with CF now reach adulthood, with the median predicted survival now about 37 yrs with
respiratory disease being the primary cause of mortality. Mannitol is an osmotic agent that increases
water content of the airway surface liquid and improves mucociliary clearance. Two 6 month phase III
studies assessing the efﬁcacy and safety of inhaled dry powder mannitol (IDPM) or control (C), twice
daily have been performed.
Methods: Efﬁcacy and safety data from these 2 randomised, double-blind, controlled phase III studies
of IDPM was combined for analysis for patients 18 yrs. Baseline data for the 341 adult patients is:
mean age 28.6 yrs; males 58.1%; baseline % predicted FEV1 (mean+SD) 59.3±15.6%; 60.7% of pts
on rhDNase. Data presented is from the 26 wk DB phase.
Results: Mean change from baseline (wk 6−26) in FEV1 for IDPM was 91.63mL (95%CI 50.22,
133.05) compared to −7.87mL (95%CI −52.16, 36.42) on C (D99.50mL [95%CI 49.14, 149.87,
p< 0.001]). Increase in FEV1 was seen regardless of concomitant rhDNase, D94.06mL (95%CI
29.70, 158.42, p = 0.004) and D110.28mL (95%CI 29.93, 190.62, p = 0.007] for rhDNase users and
non-users, respectively.
There was a positive trend with a 24.1% reduction of exacerbations with IDPM in the incidence
of protocol deﬁned pulmonary exacerbations. Serious AEs in the IDPM and C arms were 22.7%
and 26.9% respectively. Most common treatment related AE’s were cough (IDPM 12.1%, C 6.0%),
haemoptysis (IDPM 5.8%, C 3.0%) and condition aggravated (IDPM 4.8%, C 3.7%).
Conclusion: In a well treated group of adult CF patients IDPM shows signiﬁcant improvements in
FEV1. This further supports the efﬁcacy of inhaled mannitol treatment in CF.
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Patients with CF have lungs infected early in life causing a cycle of inﬂammation
and damage. As mannitol is a substrate for growth in vitro of some organisms it is
important to review the safety of inhaled mannitol (Bronchitol).[1−3]
Methods: Sputum samples (if unobtainable a pharyngeal throat swab) were taken
at wks 0, 6, 14 & 26 from the mannitol and control arms of the CF-301 &
CF302 studies. Regular standard CF clinic laboratory procedures at each site
were used to deﬁne the sputum pathogens screened for. Standard laboratories were
used for determining level of growth. A separate collection procedure and central
laboratory processing was conducted to determine quantitative sputum microbiology
for S. aureus and P. aeruginosa in the CF302 study.
Results: Qualitative sputum microbiology data at baseline from the phase III studies
was similar for the mannitol and control groups. The 3 most common bacterial
morphotypes isolated at screening were P. aeruginosa (mucoid and non-mucoid);
and S. aureus. B. cepacia was isolated at baseline in 5.4% of subjects.
At wk 26 the % of subjects with abnormal ﬂora was similar to baseline in both
groups. Furthermore quantitative sputum microbiology results from the CF302 study
for S. aureus and P. aeruginosa demonstrated no difference between the mannitol
and control groups after 26wks of therapy.
Conclusions: The combined analysis from 2 phase III trials, provide no evidence
for an increase in growth of microorganisms with inhaled mannitol in CF and
supports the ﬁnding of a lower exacerbation rate on mannitol.[2,3]
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